30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: NuVasive

4Q13 revenue: $190.8MM, +15% (Ex-U.S. +40

  • U.S. Lumbar +12%
  • U.S. Cervical +17%
  • U.S. Biologics+12%
  • Impulse Monitoring +15%

 

2013 revenue: $685.2MM, +11% (Ex-U.S. >$70MM, +30%+)

  • U.S. Lumbar +8%
  • U.S. Cervical +21%
  • U.S. Biologics +5%
  • U.S. Monitoring flat

 

  • Appointed exclusive distributor in Argentina
  • 2nd-gen VuePoint posterior cervical system at >$1MM in sales
  • Does not expect PODs to materially benefit U.S. growth in 2014
  • Estimates that less-invasive solutions claimed ~27% of global market in 2013
  • Adding more posterior fixation tools in 2014/2015
  • Not expecting to hear more on AttraX from FDA until 4Q
  • Noted future plans to enter deformity market

 

2014 forecast: ~$725MM, +6% (Ex-U.S. +20%+)

  • U.S. Lumbar +5%
  • U.S. Cervical +12%
  • U.S. Biologics +1%
  • U.S. Monitoring flat